← Back to patent-cliff list
Nafamostat intravenous (Lowell Therapeutics)
Tier C — Watch / tradeNafamostat intravenous (Lowell Therapeutics)
Lowell Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Serine protease
Indications (approved)：Acute respiratory distress syndrome, 弥漫性血管内凝血, COVID-19, 胰腺炎
Regional status
US
Phase II
2024-02-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nafamostat intravenous (Lowell Therapeutics)?
Approved indications include: Acute respiratory distress syndrome, 弥漫性血管内凝血, COVID-19, 胰腺炎.
When does the Nafamostat intravenous (Lowell Therapeutics) patent expire?
No public expiry year is available for Nafamostat intravenous (Lowell Therapeutics) yet; this page updates once verified.
How do I get a quote for Nafamostat intravenous (Lowell Therapeutics) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02